<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01897701</url>
  </required_header>
  <id_info>
    <org_study_id>NVX900.PH7.101</org_study_id>
    <nct_id>NCT01897701</nct_id>
  </id_info>
  <brief_title>A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1</brief_title>
  <official_title>A Phase 1 Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Anhui/1/2013 (H7N9) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Adults With and Without Adjuvant 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novavax</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novavax</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, observer-blinded, placebo-controlled trial in adults ≥18 years old.&#xD;
      Randomization will be stratified by age (18 to 49 years and ≥50 years) and by prior influenza&#xD;
      immunization within the past three months. Proportions of subjects in the various strata will&#xD;
      not be pre-specified; rather, the goal will be to achieve an approximately equal distribution&#xD;
      of subjects with these characteristics across the various treatment groups.&#xD;
&#xD;
      Treatments will comprise two identical IM doses at a 21-day interval (Day 0 and Day 21), in&#xD;
      alternate deltoids. For each subject, study follow-up will span approximately 385 days total,&#xD;
      or approximately 13 months from the first dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Safety</measure>
    <time_frame>Day 0 to Day 384</time_frame>
    <description>Number (and percentages) of subjects with solicited local and systemic AEs over the seven days post-injection and all adverse events, solicited and unsolicited, including adverse changes in clinical laboratory parameters, over 35 days post-first injection.&#xD;
Significant New Medical Conditions, Medically Attended Events and Serious Adverse Events will be collected for one year post-second injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity as assessed by hemagglutination-inhibiting (HAI) antibody titers against the vaccine-homologous A/Anhui/1/13 (H7N9) virus.</measure>
    <time_frame>Day 0 to Day 384</time_frame>
    <description>Geometric mean titer (GMT)&#xD;
Geometric mean ratio (GMR)&#xD;
Seroconversion rate (SCR)&#xD;
Seroresponse rate (SRR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as assessed by neuraminidase-inhibiting antibodies to N9.</measure>
    <time_frame>Day 0 to Day 384</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">280</enrollment>
  <condition>Avian Influenza</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 &amp; 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 &amp; 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate dose Monovalent Avian Influenza VLP (H7N9) and Low dose Adjuvant 1; IM; Day 0 &amp; 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose Monovalent Avian Influenza VLP (H7N9) and Low dose Adjuvant 1; IM; Day 0 &amp; Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate dose Monovalent Avian Influenza VLP (H7N9) and High dose Adjuvant 1; IM; Day 0 &amp; 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose Monovalent Avian Influenza VLP (H7N9) and High dose Adjuvant 1; IM; Day 0 &amp; 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo; IM; Day 0 &amp; 21</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent Avian Influenza VLP (H7N9)</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvant 1</intervention_name>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group G</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following to be eligible for participation in the study:&#xD;
&#xD;
          1. Healthy adult male or female, ≥18 years of age,&#xD;
&#xD;
          2. Willing and able to give informed consent prior to study enrollment,&#xD;
&#xD;
          3. Able to comply with study requirements, and&#xD;
&#xD;
          4. Women of childbearing potential must have a negative urine pregnancy test prior to&#xD;
             each vaccination, will be advised through the Informed Consent process to avoid&#xD;
             becoming pregnant over the duration of the study, and must assert that they will&#xD;
             employ an effective form of birth control for the duration of the study. Acceptable&#xD;
             forms of birth control are: credible history of continuous abstinence from&#xD;
             heterosexual activity or prior surgical sterilization, hormonal contraceptives (oral,&#xD;
             injectable, implant, patch, ring), barrier contraceptives (condom or diaphragm), and&#xD;
             intrauterine device (IUD). Women with an adequately documented history of surgical&#xD;
             sterility, or ≥50 years of age and without menses for ≥ 1 year are exempt from urine&#xD;
             pregnancy testing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects meeting any of the following criteria are not eligible for participation in the&#xD;
        study.&#xD;
&#xD;
          1. Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care.&#xD;
&#xD;
               -  Asymptomatic conditions or findings (e.g., mild hypertension, dyslipidemia) that&#xD;
                  are not associated with evidence of end-organ damage are not exclusionary&#xD;
                  provided that they are being appropriately managed and are clinically stable&#xD;
                  (i.e., unlikely to result in symptomatic illness within the time-course of this&#xD;
                  study) in the opinion of the investigator.&#xD;
&#xD;
               -  Note that illnesses or conditions may be exclusionary, even if otherwise stable,&#xD;
                  due to therapies used to treat them (see exclusion criteria 2, 5, 7, 8).&#xD;
&#xD;
          2. Participation in research involving investigational product (drug / biologic / device)&#xD;
             within 45 days before planned date of first vaccination.&#xD;
&#xD;
          3. History of a serious reaction to prior influenza vaccination.&#xD;
&#xD;
          4. History of Guillain-Barré Syndrome (GBS) within 6 weeks following a previous influenza&#xD;
             vaccine.&#xD;
&#xD;
          5. Received any vaccine in the 4 weeks preceding the study vaccination; or any A(H7N9)&#xD;
             avian influenza vaccine at any time.&#xD;
&#xD;
          6. Any known or suspected immunosuppressive condition, acquired or congenital, as&#xD;
             determined by history and/or physical examination.&#xD;
&#xD;
          7. Chronic administration (defined as more than 14 continuous days) of immunosuppressants&#xD;
             or other immune-modifying drugs within 6 months prior to the administration of the&#xD;
             study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a&#xD;
             systemic dose ≥10 mg of prednisone per day or equivalent. The use of topical, inhaled,&#xD;
             and nasal glucocorticoids will be permitted.&#xD;
&#xD;
          8. Administration of immunoglobulins and/or any blood products within the 3 months&#xD;
             preceding the administration of the study vaccine or during the study.&#xD;
&#xD;
          9. Acute disease at the time of enrollment (defined as the presence of a moderate or&#xD;
             severe illness with or without fever, or an oral temperature &gt;38.0°C on the planned&#xD;
             day of vaccine administration).&#xD;
&#xD;
         10. Known disturbance of coagulation.&#xD;
&#xD;
         11. Women who are pregnant or breastfeeding, or plan to become pregnant during the study.&#xD;
&#xD;
         12. Suspicion or recent history (within one year of planned vaccination) of alcohol or&#xD;
             other substance abuse.&#xD;
&#xD;
         13. Any condition that in the opinion of the investigator would pose a health risk to the&#xD;
             subject if enrolled or could interfere with evaluation of the vaccine or&#xD;
             interpretation of study results (including neurologic or psychiatric conditions deemed&#xD;
             likely to impair the quality of safety reporting).&#xD;
&#xD;
         14. Persons employed in a capacity that involves handling poultry or wild birds.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D. Nigel Thomas, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Novavax, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Q-Pharm Pty Limited</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMAX</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://novavax.com/</url>
    <description>Novavax Homepage</description>
  </link>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>July 9, 2013</study_first_submitted>
  <study_first_submitted_qc>July 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <last_update_submitted>October 10, 2014</last_update_submitted>
  <last_update_submitted_qc>October 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>H7N9</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

